שווי פעילות לרווח לפני ריבית, מסים ופחת Passage Bio (PASG)

Passage Bio, Inc. (PASG) specializes in developing gene therapies for brain pathologies, leveraging exclusive patents and orphan drug status to ensure long-term dominance. The company invests massive resources into the study of viral vectors, backed by a robust scientific foundation. A stable team of experts guarantees the protection of its intellectual capital. This market valuation chart for Passage Bio, Inc. (PASG) on GURU.Markets shows a value of 0.00.

The EV/EBITDA multiple determines the business value relative to its operating profit before depreciation, taxes, and interest, allowing for an assessment of the asset's real value regardless of debt load. By analyzing the EV/EBITDA multiple on a time chart, an investor correlates the capital-intensive R&D expenditures of Passage Bio, Inc. (PASG) and the patent protection of AAV vectors with strict FDA oversight, which confirms the company's fundamental resilience under regulatory pressure.